Zentalis appoints Eastland as CEO, Bruns as CMO, Myers as Chairperson

Zentalis Pharmaceuticals (ZNTL) announced changes to its executive leadership team to support the Company as it plans and executes registrational studies for its lead product candidate, azenosertib. Julie Eastland has been appointed Chief Executive Officer, President and Director, succeeding Kimberly Blackwell, M.D., who will remain as a strategic advisor to the Board of Directors. Eastland previously served as Chief Executive Officer at Harpoon Therapeutics until the company’s acquisition by Merck (MRK) in early 2024. In addition to Ms. Eastland’s appointment, Ingmar Bruns, M.D., has been appointed Chief Medical Officer, CMO. The Company also announced that Scott Myers has been appointed as Chairperson of the Zentalis Board of Directors.